Skip to content. | Skip to navigation

Personal tools

  • Le CIRI sur Linkedin
Sections

Managing bodies

logo Inserm      logo cnrslogo ENSL       logo ucb1


Secondary managing bodies

logo ENSL logo ucb1

You are here: Home / Teams / Lina B - VirPath / M. Rosa-Calatrava group / Grants and Funding

Grants and Funding

 

ANR generic call AAPG2022-MucRNAvax

Design and evaluate LipoParticulate mRNA vaccine carrier, able to cross physical barriers of the respiratory tract and to induce mucosal immune response against viral respiratory infectious diseases
2022-2026

Coordinator : LBTI

Parners : VirPath, GIMAP, IVPC

 

 

NSB CNRS (soutien COVID19)

Drug repurposing approaches for COVID-19.

Coordinateur VirPath

 

PSPC-COVID-19 (PIA) BPI

Solutions thérapeutiques, préventives ou curatives contre le COVID-19.

Coordinateur : OSIVAX, Project leaders : INSERM, Cochin Vaccine Evaluation Center APHP, Cynbiose and Virapth 

 

Projet ANR RA-COVID19 - CHROMACoV 

Role of pro-inflammatory cytokines, PML nuclear bodies, and the HIRA histone chaperone complex in epigenetic changes associated to SARS-CoV-2 infection. 

Coordinateur: INMG; Partenaires : VirPath, CRSA/Sorbonne Université. 

 

Fondation ARC EPONAC  

Proteomics, cellular co-receptor and SARS-CoV-2.

Coordinateur : CRCL;  VirPath (Partners)

 

Installations de Recherche et d’Innovation Centrées Entreprises, IRICE, Région Auvergne Rhône-Alpes, Union Européenne FEDER

Innobiovir « Innovation Bioproduction Virus » : Alliance de plateformes technologiques dans le domaine des vaccins viraux et leurs procédés de production.

2020 – 2025. Teams : VirNext, VirPath (co-coordinateur), Lagepp UMR-CNRS 5007, IUT Génie biologique UCBL1. 

 

IMI2-RIA H2020-JTI-IMI2-2020-21-single-stage

Projet CARE (Corona Accelerated R&D in Europe) 35 M€.

Coordinateur : INSERM, Project leaders : Janssen Pharmaceutica et Takeda, Partners : CEA, Helmholtz-Zentrum, LUMC, Boehringer Ingelheim, Novartis, Pfizer, Merck, Bayer…).

 

REACTing – Projet initiative Anti2019-nCoV

Repositionnement thérapeutique.

VirPath (coordinateur) 

 

REACTing – Projet initiative

In vivo titration of the SARS-CoV-2 in Cynomolgus Macaques.

IDMIT CEA (coordinateur); Partenaires : VirPath, Institut Pasteur Paris 

 

Merieux research grant

Repositionnement thérapeutique de médicaments.

VirPath (Coordinateur) 

 

Instituts de recherche en santé du Canada

Innovative therapeutic approaches for the 2019-novel coronavirus (SARS-CoV-2).

CHUQ, Université Laval, Québec (coordinateur); Partners: International Vaccine Centre (VIDO-InterVac) University of Saskatchewan, National Research Council NRC Ottawa, VirPath 

 

Région AURA -  COVIBIOSE

Mise au point d’un modèle primate non humain d’infection par le virus SARS-CoV-2 pour l’évaluation de candidats thérapeutique.

VirPath (co-coordinateur), Cynbiose SA (co-coordinateur), Vetagrosup 

 

ANR Flash-COVID-19 – Anti-CoV-Path

Pathogenesis of SARS-CoV-2 infection in NHP model : insights for treatment and prévention.

IDMIT CEA (coordinator); Partners: Institut Pasteur, INSERM UMR 1137, CIIL U1019, UMR9017, IBS-CHUGA, VirPath 

 

ANR Flash-COVID-19 – AM-CoV-Path

Approche thérapeutique.

CIIL U1019, UMR9017 (coordinator); Partners: IDMIT CEA, VirPath

 

ANR Flash-COVID-19 – COVID-I2A Therapy

Antiviral approach against the coronavirus SARS-CoV-2.

CNRS FR3636 Paris Descartes Mort cellulaire programmée et signalisation (coordinator); Partners: INSERM UMR_S94I Paris Diderot  Génétique des Virus et Pathogénèse des Maladies Virales, Institut de Génétique UMR 9002, Montpellier, VirPath

 

AAP Flash COVID Sorbonne University – Projet CoVNucleovir.

INSERM U938 CRSA, SU (coordinateur); Partenaires : CNRS UMR 8226 SU,  INSERM U938 CRSA, SU, VirPath

 

AAP Région Hauts de France – Projet CritiSARS2.

CHU Lille (coordinateur); Partenaires: CRB et CIC, CHU Lille, MCV, CIIL, INSERM U1019-CNRS UMR9017, ULR3610 “Viral pathogenesis”, VirPath 

 

Maturation COVID-19 – SATT PULSALYS

Antiviral approach against SARS-CoV-2.

VirPath (coordinator)

 

Projet de maturation Glycoflu – SATT Linksium, Grenoble

Développement et évaluation de nouveaux composés sialosides issus d’un procédé microbiologique industriel de production, ayant un potentiel d’inhibiteur de virus influenza.

2020 – 2021. Teams : CERMAV CNRS UPR5301/coordinateur, VirNext, VirPath.

 

R&D BOOSTER Région Auvergne Rhône-Alpes, BPI France, EU FEDER

Development and characterization of a new pre-clinical NHP model of HMPV infection to evaluate repurposed drugs.

2020-2021 - Teams: Signia Therapeutics (coordinator), VirPath and Cynbiose

 

ANR AAP19 METAVAC-T17

Characterization and up scaling of a DuckCeltTM-T17 cell suspension culture process for the production of a new live-attenuated hRSV/hMPV chimeric METApneumovirus-based VACcine.

2019-2022 - Teams :  VirPath (coordinator), LAGEPP UMR-CNRS 5007 and UVIM-UR0892

 

IDEXLYON Breakthrough program WANTED.

(Which Atmospheric Nanoparticles Trigger hEatlh Diseases?).

2018-2021 - Teams : IRCELYON (Principal Investigator), CarMeN, ISA, Legionella pathogenesis team and VirPath

 

METAVAC - Maturation Program funded by the Technology Transfer Accelerator Office PULSALYS.  Development of a new live attenuated viral vaccine and optimized upscalable avian cell line-based process for production. 

2019-2020 VirPath (Principal investigator)

 

REPURPOSING - Maturation Program funded by the Technology Transfer Accelerator Office PULSALYS.

Pre-clinical evaluation of a repurposed drug for new antimicrobial indication.

2019-2020 VirPath (Principal investigator)

 

VLM grant (Vaincre la Mucoviscidose)

Study of co-infections between influenza & bacteria in healthy versus Cystic Fibrosis 3D reconstituted human airway epithelia.

2018 - VirPath (Principal Investigator)

 

Fondation Air Liquide: COEPIMUS

Mieux comprendre les mécanismes de pathogenèse entre virus et bactéries à l’échelle de l’épithélium respiratoire dans le contexte des pathologies respiratoires chroniques.

2019-2020 VirPath (Principal investigator)

 

CIRI Funding 2018

The lung-on-a-chip as a new platform for studying respiratory diseases.

2018 - Teams : Legionella pathogenesis (Principal investigator), Staphylococcus pathogenesis and VirPath

 

FINOVI 11th : COEPI

Signatures of bacterial-viral co-infections in healthy versus Cystic Fibrosis 3D reconstituted human airway epithelia.

2017 - VirPath (Principal Investigator)

 

CSIC Uruguay R&D Program.

Design of TWIN compounds with antiviral activity against influenza and respiratory syncytial viruses.

2017 – University of the Republic Uruguay ; VirPath (Co-Principal Investigator)

 

FINOVI 10th: IDEA-FLU

Innovative nano DElivery systems for Influenza Antigens.

2016 - CEA Leti ; Institut Albert Bonniot (IAB) U823 INSERM Université Grenoble

 

CIRI Funding 2017

Study of the effect of fusion inhibitory peptides in the prevention and treatment of influenza virus infection.

2017 - Teams : Immunobiology of Viral infections and VirPath

 

PHRC : FLUNEXT Clinical trial. 

Confirmation of the Antiviral Effects of repurposed drugs. 

Jan. 2016 - CHRU de Lille ; VirPath.

Triggersep label.

 

ANR : Psi-FLU project

Sequence and structure of the packaging signals of the influenza A virus genome.

Sept. 2015 - IBMC Architecture et Réactivité de L'ARN CNRS UPR 9002

 

FINOVI 9th: FLUCUBE

Purification of in vivo influenza virus crystalline structures in order to characterize the complete NS1 protein structure

2015 - IBS ; VirPath (Principal investigator)

 

CMIRA Accueil PRO (Auvergne-Rhône-Alpes)

Programme d’aide à la mobilité des chercheurs étrangers de la région Auvergne-Rhône-Alpes.

2015 VirPath (Principal Investigator)

 

ANR : OPTIVAC project

leveraging On cellular immune resPonse To Improve flu VACcines.

Jan. 2014 - Imaxio ; CIRI U1111 INSERM - UMR 5308 CNRS - ENS Lyon - UCBL1

 

ANR : BioVirSafe (LabCom) project

Laboratoire Commun de recherche et développement de biocides pour la maîtrise des contaminations microbiologique.

Jan. 2014 - PSA (Produits Sanitaires Aéronefs, Paris) ; VirPath (Principal investigator)

 

ANR-PRTS : Cov-Sign project

Identification of novel inhibitors against emerging human coronaviruses MERS-CoV and SARS-CoV from in vivo transcriptionnel.

Jan. 2014 - Institut Pasteur - CNRS UMR3569 ; CIIL Inserm U1019 CNRS UMR8204 ; CHRU de Lille ; ProfileXpert ; VirPath (Principal investigator)

Lyon Biopole label.

 

FP7 Marie Curie actions: FLU-MAL VLP project

Chimeric Influenza-VLP used as vaccine platform for presentation of foreign antigens, application to Malaria antigens.

Jan. 2013 - VirPath (Principal investigator)

 

CMIRA program (Rhône-Alpes)

Programme de coopération structurante de la région Rhône-Alpes avec la région de Québec.

Jan. 2013  VirPath (Principal investigator)

 

PHRC : FLUMED Clinical trial (NCT01546506). 

Confirmation of the Antiviral Effects of Midodrine Identified With a Gene Expression Signature-based Screening of Inluenza A Virus Infected Cells. 

Jan. 2012 - Hospices Civils de Lyon ; Université Claude Bernard Lyon 1 ; Virpath (Principal investigator)

 

FUI : COV-KO project

Réalisation d’appareils sécurisés (autonomes et intégrés) de traitement de l’air intérieur « 0 » COV, « 0 » odeur.

Jan. 2012 – BMES ; Brochier ; Tera Environnement ; ALDEBO ; ETHERA ; Atlantic ; IRCE Lyon UMR 5256 CNRS

Axelera Label

 

BQIP : VirNext platform

Bonus qualité relations industrielles plateformes 2012.

Jan. 2012 – VirNext ; Université Claude Bernard Lyon 1; Ezus

 

Maturation de Projets Innovants : FLUVAC project 

New compounds

Jan. 2012 – Université Claude Bernard Lyon 1 ; SATT Pulsalys ; VirPath (Principal Investigator)

 

FUI : FLURIAD project

Mucous administration of anti-influenza vaccine.

Jan. 2011 - Onxeo ; Université Paris Sud EA 401; Sogeval ; Gredeco ; CHU de Nice.

Medicen label.

 

APP Recherche Clinique Translationnelle : FLUNEXT project

Transcriptomic signature of influenza from pandemic H1N1 infected patients.

Jan. 2010 - Inserm ; DHOS

 

BQIP : FLUVAX project

Bonus Qualité Relations Industrielles (UCBL).

Jan. 2010 – Université Claude Bernard Lyon 1 ; SATT Pulsalys ; VirPath (Principal Investigator)

 

Maturation de Projets Innovants : FLUGP project

Optimisation du procédé de production des glycoprotéines des semences vaccinales.

Jan. 2010 - UCBL ; Lyon Science Transfert

 

FUI : SAVAB project.

Anti-microbiologic systems.

Jan. 2010 - Aelovre.

Pegase label.